Resistance to non-depolarizing neuromuscular blocking agents.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  British Journal of Anaesthesia

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 1836340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Resistance to atracurium in a patient with an increase in plasma alpha 1 globulins.

  1991cited by this paper
• Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis.

  1989cited by this paper
• The Pharmacokinetics of Atracurium Isomers In Vitro and in Humans

  1987cited by this paper
• The Effect of Phenytoin on the Magnitude and Duration of Neuromuscular Block Following Atracurium or Vecuronium

  1987cited by this paper
• Measurement of acetylcholine receptor concentration in skeletal muscle from a patient with multiple sclerosis and resistance to atracurium.

  1987cited by this paper
• Plasma Drug Binding: Implications for Anesthesiologists

  1986cited by this paper
• The plasma protein binding of basic drugs.

  1986cited by this paper
• Use of atracurium and vecuronium in patients with oesophageal varices.

  1985cited by this paper
• Pharmacokinetics and Pharmacodynamics of Vecuronium (ORG NC 45) in Patients with Cirrhosis

  1985cited by this paper
• Comparison of vecuronium, atracurium and tubocurarine in normal patients and in patients with no renal function.

  1984cited by this paper
• The Pharmacokinetics and Pharmacodynamics of Atracurium in Patients with and without Renal Failure

  1984cited by this paper
• Metabolism and kinetics of atracurium: an overview.

  1983cited by this paper
• Protein binding of atracurium and other short-acting neuromuscular blocking agents and their interaction with human cholinesterases.

  1983cited by this paper
• The Effects of Hypercarbia and Hypocarbia on Pancuronium and Vecuronium Neuromuscular Blockades in Anesthetized Humans

  1983cited by this paper
• Plasma Binding of Pancuronium: Effects of Age, Sex, and Disease

  1983cited by this paper
• Binding of tubocurarine, fazadinium, pancuronium and Org NC 45 to serum proteins in normal man and in patients with cirrhosis.

  1982cited by this paper
• Disuse atrophy with resistance to pancuronium.

  1981cited by this paper
• Pharmacokinetics of Org NC45 (norcuron) in patients with and without renal failure.

  1981cited by this paper
• Elevated Plasma Binding Cannot Account for the Burnrelated d‐Tubocurarine Hyposensitivity

  1981cited by this paper
• Monitoring neuromuscular block may be unreliable in patients with upper-motor-neuron lesions.

  1980cited by this paper
• Pancuronium pharmacokinetics in patients with liver cirrhosis.

  1979cited by this paper
• The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide

  1977cited by this paper
• Binding of d‐Tubocurarine to Plasina Proteins in Normal Man and in Patients with Hepatic or Renal Disease

  1973cited by this paper
• Pancuronium bromide

  1972cited by this paper
• Sensitivity to gallamine and pancuronium with special reference to serum proteins.

  1971cited by this paper
• Sensitivity to tubocurarin and alcuronium with special reference to plasma protein pattern

  1971cited by this paper
• Correlation between tubocurarine requirements and plasma protein pattern.

  1968cited by this paper
• Neuromuscular and Electromyographic Studies in Man: Effects of Hyperventilation, Carbon Dioxide Inhalation and d‐Tubocurarine

  1964cited by this paper

• Acute tolerance to rocuronium -A case report-

  2024cites this paper
• Evaluation of Rocuronium Continuous Infusion in Critically Ill Patients During the COVID-19 Pandemic and Drug Shortages

  2021cites this paper
• Resistance to non-depolarizing neuromuscular blocking agents

  2020cites this paper
• PHARMACOKINETIC CHANGES IN NMBA RESISTANCE

  2018cites this paper
• Utilización de bloqueantes neuromusculares en el paciente crítico

  2008cites this paper
• Atracurium and laudanosine pharmacokinetics in acute renal failure

  2005cites this paper
• Resistance to cisatracurium in a patient with MELAS syndrome

  2005cites this paper
• Repeated Resistance to Non-depolarizing Neuromuscular Blocking Drugs in a Patient with Multiple Myeloma Sir,—we Read with Interest the Article

  2005cites this paper
• Cisatracurium infusion for neuromuscular blockade in the pediatric intensive care unit: A dose-finding study

  2002cites this paper
• Increased sensitivity to vecuronium and prolonged duration of its action in patients with end-stage renal failure.

  2001cites this paper
• SKELETAL MUSCLE RELAXANTS: PHARMACODYNAMICS AND PHARMACOKINETICS IN DIFFERENT PATIENT GROUPS

  2000cites this paper
• Atracurium during thoracic surgery: impaired efficiency in septic processes.

  1999cites this paper
• [The use of curare-like agents in resuscitation].

  1999cites this paper
• Clinical uses and controversies of neuromuscular blocking agents in infants and children.

  1999cites this paper
• Controlled mechanical ventilation in horses under vecuronium blockage

  1998cites this paper
• Cross‐Resistance to Both Atracurium‐ and Vecuronium‐Induced Neuromuscular Blockade in a Critically Ill Patient

  1997cites this paper
• [Postoperative resistance against atracurium].

  1997cites this paper
• Postoperative Resistenzentwicklung gegenüber Atracurium

  1997influential citation
• Resistance followed by prolonged neuromuscular block with vecuronium.

  1996cites this paper
• Resistance to Nondepolarizing Neuromuscular Blocking Agents

  1996cites this paper
• Marked mixed venous hemoglobin desaturation in a patient during hypothermic cardiopulmonary bypass.

  1995cites this paper
• Doxacurium infusion in critically ill patients with atracurium tachyphylaxis.

  1995cites this paper
• Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function.

  1995cites this paper
• Resistance to atracurium in rats with experimental inflammation: role of protein binchng

  1995cites this paper
• Mivacurium in special patient groups

  1995cites this paper
• Muscle relaxants in renal disease *

  1994cites this paper
• Repeated resistance to non-depolarizing neuromuscular blocking drugs in a patient with multiple myeloma.

  1992cites this paper
• Probable resistance to vecuronium involving the 17-hydroxy metabolite.

  1992cites this paper
• Use of mivacurium chloride by constant infusion in the anephric patient.

  1992cites this paper
• Neuromuscular blocking drugs and renal failure.

  1992cites this paper
• In vitro displacement of vasoactive mediators from plasma proteins: a possible mechanism for pseudo-allergic reactions to neuromuscular blocking drugs.

  1992cites this paper